causal attribution to specific receptor pathways requires further human data
Liraglutide was associated with a 0.23 percentage point decline in HbA1c ( P = .017), a 52.6 mg/g drop in urine albumin-to-creatine ratio ( P = .007) and a 0.25 mmol/L reduction in LDL cholesterol ( P = .02) from drug initiation to 1 year
Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection
These tradeoffs are not merely theoretical: in the pilot phase of the PRECIDENTD pragmatic trial, participants assigned to dual therapy had substantially lower medication fill rates and higher discontinuation than those on monotherapy, driven largely by side effects, cost, and access [36]
Wee Yong and the other anonymous, reviewer(s) for their contribution to the peer review of this work
Toxicol Lett 185(3):211218